Could Medigus Limited Ads (NASDAQ:MDGS) Skyrocket? The Stock Has Too Many Sellers

February 15, 2018 - By Larry Anderson

 Could Medigus Limited Ads (NASDAQ:MDGS) Skyrocket? The Stock Has Too Many Sellers

The stock of Medigus Limited Ads (NASDAQ:MDGS) registered an increase of 747.22% in short interest. MDGS’s total short interest was 30,500 shares in February as published by FINRA. Its up 747.22% from 3,600 shares, reported previously. With 243,400 shares average volume, it will take short sellers 0 days to cover their MDGS’s short positions.

The stock decreased 0.72% or $0.0099 during the last trading session, reaching $1.3701. About 5,607 shares traded. Medigus Ltd. (NASDAQ:MDGS) has declined 89.32% since February 15, 2017 and is downtrending. It has underperformed by 106.02% the S&P500.

Medigus Ltd., a medical device company, develops, makes, and markets surgical endostaplers and direct vision systems for minimally invasive medical procedures in the United States, Europe, Asia, and internationally. The company has market cap of $5.06 million. It offers MUSE, an ultrasonic surgical endostapler system for the treatment of gastroesophageal reflux disease; and miniaturized video cameras for use in various medical procedures, as well as specialized industrial applications. It currently has negative earnings.

More notable recent Medigus Ltd. (NASDAQ:MDGS) news were published by: which released: “Medigus Receives Nasdaq Letter Regarding Bid Price Compliance” on January 16, 2017, also with their article: “Medigus Announces Pricing of $1.6 Million Registered Direct” published on November 24, 2017, published: “25 Stocks Moving In Friday’s Pre-Market Session” on November 24, 2017. More interesting news about Medigus Ltd. (NASDAQ:MDGS) were released by: and their article: “Medigus prices equity offering; shares down 28% premarket” published on March 24, 2017 as well as Globes.Co.Il‘s news article titled: “Medigus raises NIS 7.5m on Nasdaq – share plunges” with publication date: March 26, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.